s36沙龙会 - 要玩就玩沙龙会

    关于我们
    研发服务
    服务平台
    客户中心
    新闻资讯
    投资者关系
    人力资源
    EN
    ×
    EN

    • 业务咨询

      中国：

      Email: marketing@lixuewei.com

      业务咨询专线：400-780-8018

      （仅限服务咨询，其他事宜请拨打川沙总部电话）

      川沙总部电话: +86 (21) 5859-1500

      海外：

      +1(781)535-1428(U.S.)

      0044 7790 816 954 (Europe)

      Email:marketing@medicilon.com
    在线留言×
    点击切换
    Customer Center
    客户中心
    Jul 06,2023
    以PROTAC为代表的靶向蛋白质降解是药物发现的新兴策略，研究人员设计并合成了多种PROTAC，此研究中所有PK研究均通过s36沙龙会进行
    Targeted protein degradation (TPD) exemplified by PROTACs is an emerging strategy for next generation drug discovery. Threonine tyrosine kinase (TTK) is a dual-specific protein kinase that catalyzes phosphorylation of both serine/threonine and tyrosine residues. Researchers designed and synthesized TTK PROTACs, which demonstrated reasonable pharmacokinetic profiles. All the pharmacokinetic studies were carried out by Medicilon, according to the protocols and guidelines of the institutional care and use committee.
    查看更多
    以PROTAC为代表的靶向蛋白质降解是药物发现的新兴策略，研究人员设计并合成了多种PROTAC，此研究中所有PK研究均通过s36沙龙会进行
    Jul 06,2023
    氯磺丙脲对蠕虫和人肺成纤维细胞MRC-5细胞具有抗衰老作用，氯磺丙脲在小鼠中的生物利用度测定通过s36沙龙会进行
    Sulfonylureas exert their anti-diabetic effects by inhibiting K-ATP channels in the plasma membrane of islet β-cells. Chlorpropamide acts on complex II directly or indirectly via mitoK-ATP to produce mtROS as a pro-longevity signal. Chlorpropamide has an anti-aging effect on worms and human lung fibroblast MRC-5 cells. Determination of Chlorpropamide bioavailability in mice was performed by Medicilon.
    查看更多
    氯磺丙脲对蠕虫和人肺成纤维细胞MRC-5细胞具有抗衰老作用，氯磺丙脲在小鼠中的生物利用度测定通过s36沙龙会进行
    Jul 06,2023
    BRD4抑制剂可用于治疗肾纤维化，ZLD2218可有效抑制BRD4活性，对ZLD2218的PK研究通过s36沙龙会进行
    Uncovering new therapeutics for kidney fibrosis hold promise for chronic kidney disease (CKD). BRD4 inhibition ameliorated kidney injury and fibrosis. ZLD2218 exhibited the potent inhibitory activity against BRD4, with the IC50 value of 107 nM. Pharmacokinetic analysis of of ZLD2218 were analyzed by noncompartmental methods using Phoenix WinNonlin 7.0 (Accomplished by Medicilon).
    查看更多
    BRD4抑制剂可用于治疗肾纤维化，ZLD2218可有效抑制BRD4活性，对ZLD2218的PK研究通过s36沙龙会进行
    Jul 06,2023
    免疫检查点阻断疗法改变了癌症治疗的范式，此研究中通过s36沙龙会在23 个同源肿瘤模型中进行了抗PD-1抗体的体内研究
    Immune checkpoint blockade therapies have changed the paradigm of cancer therapies. Reseachers performed in vivo screening for anti-PD-1 therapy across 23 syngeneic tumor models and found that CT-26 and Colon 26, which are murine colorectal carcinoma derived from BALB/c mice, showed different sensitivity to anti-PD-1. In vivo studies for anti-PD-1 antibody across 23 syngeneic tumor models were performed by Medicilon.
    查看更多
    免疫检查点阻断疗法改变了癌症治疗的范式，此研究中通过s36沙龙会在23 个同源肿瘤模型中进行了抗PD-1抗体的体内研究
    Jul 06,2023
    PDE1是与中枢和外周疾病密切相关的药物靶点，研究人员合成一种PDE1 抑制剂在大鼠肝微粒体中具有良好的代谢稳定性。其中稳定性测试通过s36沙龙会进行
    Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat liver microsomes. Stability test in the rat liver microsomes were performed by Medicilon.
    查看更多
    PDE1是与中枢和外周疾病密切相关的药物靶点，研究人员合成一种PDE1 抑制剂在大鼠肝微粒体中具有良好的代谢稳定性。其中稳定性测试通过s36沙龙会进行
    Jul 06,2023
    SKLB-YTH-60可改善博来霉素诱导的肺纤维化小鼠模型中的炎症和纤维化，YTH-60的体内药代动力学研究通过s36沙龙会进行
    Idiopathic pulmonary fibrosis is a chronic and lethal lung disease associated with fibroblast activation, myoblast proliferation and extracellular matrix deposition. SKLB-YTH-60 was developed through computer-aided drug design, de novo synthesis and high-throughput screening. YTH-60 has obvious anti‐proliferative activity on fibroblasts and A549 cells. YTH-60 has an acceptable oral bioavailability and appropriate eliminated half-life time. The in vivo pharmacokinetic study of YTH‐60 was performed by Medicilon.
    查看更多
    SKLB-YTH-60可改善博来霉素诱导的肺纤维化小鼠模型中的炎症和纤维化，YTH-60的体内药代动力学研究通过s36沙龙会进行
    Jul 06,2023
    研究人员成功发现了一种口服PROTAC降解剂SIAIS164018，具有良好的体内耐受性。PK和MTD研究通过s36沙龙会进行
    PROTAC is an attractive technology in drug discovery. Researchers successfully discovered an orally available PROTAC degrader SIAIS164018 which degrades not only ALK or mutant EGFR but also oncoproteins involved in metastasis. SIAIS164018 is orally bioavailable and well tolerated in vivo. Pharmacokinetic and maximal tolerated dose (MTD) assays were performed by Medicilon.
    查看更多
    研究人员成功发现了一种口服PROTAC降解剂SIAIS164018，具有良好的体内耐受性。PK和MTD研究通过s36沙龙会进行
    Jul 06,2023
    开发具有口服活性的高度选择性卵泡刺激激素受体激动剂，且进行临床前研究。其中对大鼠和狗的毒理学评估通过s36沙龙会进行
    TOP5300 is an orally active follicle stimulating hormone receptor allosteric agonist that provides a preferred treatment for over 16 million infertile women of reproductive age in low complexity methods or in high complexity methods. TOP5300 was evaluated in standard ADME, including Cytochrome P450 inhibition, clearance and pharmacokinetic profiles. Toxicological evaluations were performed in both rat and dog as the second species according to the guidance from FDA. These assays were performed by Medicilon.
    查看更多
    开发具有口服活性的高度选择性卵泡刺激激素受体激动剂，且进行临床前研究。其中对大鼠和狗的毒理学评估通过s36沙龙会进行
    Jul 06,2023
    PARP1/2抑制剂有治疗肿瘤的潜力，PARP1/2抑制实验通过s36沙龙会进行
    Poly ADP-ribose polymerases (PARPs) are a family of enzymes related to DNA damage repair process. Inhibition of PARP1/2 accelerates the damage of injured DNA, which is synthetically lethal to DNA-repairing-deficient cancer cells, such as BRCA1/2-deficient cells. PARP1/2 inhibitors could be a promising candidate for the treatment of cancer. The PARP1 and PARP2 inhibition assays were performed by Medicilon.
    查看更多
    PARP1/2抑制剂有治疗肿瘤的潜力，PARP1/2抑制实验通过s36沙龙会进行
    Jul 06,2023
    使用s36沙龙会硒代氨基酸培养基产品发表的学术文献
    s36沙龙会提供全套M9硒代蛋氨酸（SeMET）培养基，可用于IPTG诱导的大肠杆菌表达系统，生产硒代蛋氨酸标记的蛋白，运用多波长反常散射（MAD）方法进行蛋白质晶体学研究。
    查看更多
    使用s36沙龙会硒代氨基酸培养基产品发表的学术文献
    ×
    搜索验证
    点击切换
    友情链接: